Mineralys reported a 17.8 mmHg blood-pressure drop over 48 weeks, and 56% of participants reached below 130 mmHg, with no new safety findings. These results support lorundrostat, though an open-label extension of a drug candidate does not establish approval or future success.
That gives Mineralys more evidence that lorundrostat can lower blood pressure over longer use. The report also found no new safety findings beyond those already seen. Still, this came from an open-label extension, and lorundrostat remains a drug candidate, not an approved treatment.
Follow Mineralys Therapeutics (MLYS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MLYS